Evaluation and Visualization of the Right Ventricle Using Three-Dimensional Echocardiography

As neonatal right ventricular (RV) function undergoes transition from fetal to neonatal circulation, evaluation of the neonatal right ventricle is important. We analyzed the RV function of three infants with persistent pulmonary hypertension of the newborn (PPHN) using three-dimensional transthoracic echocardiography (3D echo) and herein report the results.

Pulmonary hypertension · Three-dimensional echocardiography · Right ventricular function As neonatal right ventricular (RV) function undergoes transition from fetal to neonatal circulation, evaluation of the neonatal right ventricle is important. We analyzed the RV function of three infants with persistent pulmonary hypertension of the newborn (PPHN) using three-dimensional transthoracic echocardiography (3D echo) and herein report the results.
Patient 2 was a girl born at 41 weeks (weight, 3010 g; Ap, 1/6) with neonatal asphyxia, neonatal pneumonia, and PPHN. She underwent iNO therapy and improved; 3D echo was performed before and after iNO therapy.
Patient 3 was a boy with congenital cystic adenomatoid malformation and hydrops fetalis. He was born by cesarean section at 35 weeks with uncontrollable pleural fluid and ascites. His pulmonary hypertension (PH) and respiratory condition did not improve even after thoracentesis, lobectomy, and sildenafil. He died 27 h after birth. Echocardiography was performed after lobectomy.
In each case, we performed 3D echo with an EPIQ system and X7-2 transducer (Philips Healthcare, Amsterdam, Netherlands) and analyzed the images with a TomTec system (TomTec Imaging Systems, Unterschleißheim, Germany) ( Fig. 28.1). 3D data were acquired in a full-volume data set from the four-chamber apical view. The frame rate was 50 Hz. In Patient 1, the right ventricular enddiastolic volume (RVEDV) was the same (5.7 ml) at 6 and 12 h after starting iNO therapy; however, the right ventricular stroke volume (RVSV) and right ventricular ejection fraction (RVEF) increased from 1.6 to 2.3 ml and from 28% to 40%, respectively. In Patient 2, the RVEDV slightly decreased from 5.1 to 4.9 ml before and after iNO therapy. The RVSV and RVEF increased from 1.4 to 1.9 ml and from 28% to 39%, respectively. In Patient 3, the RVEDV was 4.7 ml, RVSV was 3.5 ml, and RVEF was 27% (Fig. 28.2).
The RVEF increased in Patients 1 and 2 following the improvement of PH and remained low in Patient 3. This may suggest that RVEF is significantly correlated with PH. Murata et al. [1] reported that RVEF measured by 3D echo could help to noninvasively predict the clinical outcomes of PH. Thus, 3D echo data might be useful for evaluating patients' cardiac condition and choosing treatment.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.